Anti-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody in necrotizing myopathy: treatment outcomes, cancer risk, and role of autoantibody level.

Conclusion: HMGCR Ab-positive NM patients are associated with statin exposure, have severe muscle weakness and high CK at presentation, lack other organ manifestations, and generally have favourable outcomes from immunosuppression. Anti-HMGCR Abs should be assessed in MSA-negative NM patients, particularly those with a history of statin exposure. PMID: 31801390 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31801390?dopt=Abstract

Source: Scandinavian Journal of Rheumatology - December 4, 2019 Category: Rheumatology Authors: Aggarwal R, Moghadam-Kia S, Lacomis D, Malik A, Qi Z, Koontz D, Burlingame RW, Oddis CV Tags: Scand J Rheumatol Source Type: research